

GLAXOSMITHKLINE PLC  
Form 6-K  
January 15, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 15 January 2019

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley  
Chief Executive Officer
- b) Position/status

- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument ISIN: GB0009252882  
Ordinary shares of 19 pence each ('Ordinary Shares')

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.3600	199
£15.3600	216
£15.3600	758
£15.3600	199
£15.3600	216

Aggregated information

- d) Aggregated volume Price 1,588  
£15.3600

- e) Date of the transaction 2019-01-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position/status President, Global Vaccines

- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 19 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.3600	135
	£15.3600	113
	£15.3600	161
	£15.3600	113

- d) Aggregated information
- Aggregated volume Price 522  
 £15.3600

- e) Date of the transaction 2019-01-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S P Dingemans
- b) Position/status Chief Financial Officer
- c) Initial notification/ amendment Initial notification
- 2.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 19 pence each ('Ordinary Shares')  
 ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.3600	263
	£15.3600	197
	£15.3600	537
	£15.3600	263
	£15.3600	197

- d) Aggregated information  
 Aggregated volume Price

1,457  
 £15.3600

- e) Date of the transaction 2019-01-11  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hirons  
 b) Position/status SVP, Global Ethics & Compliance  
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 19 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.3600	97
	£15.3600	71
	£15.3600	84
	£15.3600	97
	£15.3600	71

d) Aggregated information  
Aggregated volume Price 420  
£15.3600

e) Date of the transaction 2019-01-11  
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara  
CEO, GSK Consumer  
b) Position/status Healthcare

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

a) Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053	
b) Nature of the transaction	Increase in notional interest in American Depositary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on American Depositary Shares held in the Company's Deferred Annual Bonus Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	\$ 39.3600	82
	\$ 39.3600	80
d) Aggregated information		
Aggregated volume	162	
Price	\$39.3600	
e) Date of the transaction	2019-01-11	
f) Place of the transaction	New York Stock Exchange (XNYS)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr L Miels
b) Position/status	President, Global Pharmaceuticals
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	

a) Description of the financial instrument	Ordinary shares of 19 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of

dividends paid to  
shareholders on 10 January  
2019 on Ordinary Shares held  
in the Company's Deferred  
Annual Bonus Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.3600	153
	n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e) Date of the transaction	2019-01-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr D Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 19 pence each ('Ordinary Shares') ISIN: GB0009252882
--	---

b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Performance Share Plan.
------------------------------	---

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.3600	124
	£15.3600	90
	£15.3600	156

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£15.3600 124  
 £15.3600 90

Aggregated information  
 d) Aggregated volume Price

584  
 £15.3600

e) Date of the transaction 2019-01-11  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms K Terrell  
 Chief Digital & Technology  
 Officer  
 b) Position/status

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares  
 ('ADSs')  
 ISIN: US37733W1053

b) Nature of the transaction Increase in notional interest  
 in American Depository  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 10  
 January 2019 on American  
 Depository Shares held in the  
 Company's Deferred Annual  
 Bonus Plan.

c) Price(s) and volume(s) Price(s) Volume(s)  
 \$ 39.3600 27  
 d) Aggregated information n/a (single transaction)

Aggregated volume Price



- e) Date of the transaction 2019-01-11  
 f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas  
 b) Position/status SVP, Human Resources

- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 19 pence each ('Ordinary Shares')  
 ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

- |                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.3600 | 181       |
|                           | £15.3600 | 135       |
|                           | £15.3600 | 170       |
|                           | £15.3600 | 181       |
|                           | £15.3600 | 135       |

Aggregated information

- d) Aggregated volumePrice 802£15.3600

- e) Date of the transaction 2019-01-11  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr P C Thomson
  - b) Position/status President, Global Affairs
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 19 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
  - c) Price(s) and volume(s)
 

	Price(s)	Volume(s)
	£15.3600	111
	£15.3600	85
	£15.3600	106
  - d) Aggregated information
 

Aggregated volume	302
Aggregated Price	£15.3600
  - e) Date of the transaction 2019-01-11
  - f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 15, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc